Characteristics and Dysbiosis of the Gut Microbiome in Renal Transplant Recipients

• Published in: Journal of clinical medicine 2020-02, Vol.9 (2), p.386
• Main Authors: Swarte, J Casper, Douwes, Rianne M, Hu, Shixian, Vich Vila, Arnau, Eisenga, Michele F, van Londen, Marco, Gomes-Neto, António W, Weersma, Rinse K, Harmsen, Hermie J M, Bakker, Stephan J L
• Format: Article
• Language: English
• Subjects: Antibiotics; Antihypertensives; Body mass index; Clinical medicine; Deoxyribonucleic acid; Diabetes; Diarrhea; Digestive system; Disease; DNA; Immunosuppressive agents; Kidney transplants; Medical screening; Metadata; Microbiota; Mortality; Multivariate analysis; Outpatient care facilities; Stem cells; Taxonomy; Variance analysis
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm9020386

Renal transplantation is life-changing in many aspects. This includes changes to the gut microbiome likely due to exposure to immunosuppressive drugs and antibiotics. As a consequence, renal transplant recipients (RTRs) might suffer from intestinal dysbiosis. We aimed to investigate the gut microbiome of RTRs and compare it with healthy controls and to identify determinants of the gut microbiome of RTRs. Therefore, RTRs and healthy controls participating in the TransplantLines Biobank and Cohort Study (NCT03272841) were included. We analyzed the gut microbiome using 16S rRNA sequencing and compared the composition of the gut microbiome of RTRs to healthy controls using multivariate association with linear models (MaAsLin). Fecal samples of 139 RTRs (50% male, mean age: 58.3 ± 12.8 years) and 105 healthy controls (57% male, mean age: 59.2 ± 10.6 years) were collected. Median time after transplantation of RTRs was 6.0 (1.5-12.5)years. The microbiome composition of RTRs was significantly different from that of healthy controls, and RTRs had a lower diversity of the gut microbiome ( < 0.01). Proton-pump inhibitors, mycophenolate mofetil, and estimated glomerular filtration rate (eGFR) are significant determinants of the gut microbiome of RTRs ( < 0.05). Use of mycophenolate mofetil correlated to a lower diversity ( < 0.01). Moreover, significant alterations were found in multiple bacterial taxa between RTRs and healthy controls. The gut microbiome of RTRs contained more Proteobacteria and less Actinobacteria, and there was a loss of butyrate-producing bacteria in the gut microbiome of RTRs. By comparing the gut microbiome of RTRs to healthy controls we have shown that RTRs suffer from dysbiosis, a disruption in the balance of the gut microbiome.